Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
PRMT6 is a member of the protein arginine methyltransferase family, which participates in a variety of physical processes and plays an important role in the occurrence and development of tumors. Using small molecules to design and synthesize targeted protein degraders is a new strategy for drug development. Here, we report the first-in-class degrader SKLB-0124 for PRMT6 based on the hydrophobic tagging (HyT) method.Importantly, SKLB-0124 induced proteasome dependent degradation of PRMT6 and significantly inhibited the proliferation of HCC827 and MDA-MB-435 cells. Moreover, SKLB-0124 effectively induced apoptosis and cell cycle arrest in these two cell lines. Our data clarified that SKLB-0124 is a promising selective PRMT6 degrader for cancer therapy which is worthy of further evaluation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bioorg.2024.107439 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted degradation of Werner syndrome helicase (WRN) via ligand-directed covalent hydrophobic tagging.
Eur J Med Chem
September 2025
State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, PR China. Electronic address:
The Werner syndrome RecQ helicase (WRN) has recently emerged as a novel synthetic lethality target for microsatellite instability-high (MSI-H) cancers. However, available WRN inhibitors or degraders is still lacking so far. Particularly, chemically designed probes capable of degrading WRN irrespective of microsatellite status remain unexplored.
View Article and Find Full Text PDFTargeted delivery and pro-apoptotic efficacy of an Epstein-Barr virus nuclear antigen 1-specific affibody in EBV-infected cells in vitro.
Int J Biol Macromol
September 2025
Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. Electronic address:
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) sustains viral latency and drives oncogenesis in EBV-driven malignancies such as nasopharyngeal carcinoma and lymphomas. The dimerization of EBNA1 acts as an indispensable molecular switch governing EBV latency and oncogenesis. Disruption of EBNA1 dimerization is a promising strategy, but existing small-molecule inhibitors lack sufficient specificity.
View Article and Find Full Text PDFAntifungal echinocandins: Historical discovery, comprehensive structure-activity relationships, resistance mechanisms and future developments.
Eur J Med Chem
August 2025
Chemobiology and Pharmacognosy for Health (CPS) Team, Strasbourg Institute for Drug Discovery and Development (ITI IMS), Laboratory of Therapeutic Innovation (LIT), UMR 7200 CNRS/Unistra, Faculty of Pharmacy, 74, route du Rhin, Illkirch, 67400, France; University of Strasbourg Institute for Advanced
Before the 2000s, the antifungal toolbox against invasive fungal infections (IFIs) was only composed of very toxic amphotericin B, weakly selective and nearly unused 5-fluorocytosine and azoles that have been massively used in agriculture and horticulture. The emergence of resistances followed their respective launch, so many antifungals became progressively inefficient whereas the antifungal research was left behind. In the 2000s, echinocandins (ECs) were introduced as a new antifungal class of natural origin and of unprecedented mechanism of action.
View Article and Find Full Text PDFAn allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.
Sci Transl Med
September 2025
University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
is among the most frequently mutated oncogenes in cancer, and for decades, efforts at pharmacological blockade of its function in solid cancers have been unsuccessful. A notable advance in this endeavor is the recent development of small-molecule KRAS inhibitors, which enable direct targeting of the mutant oncoprotein. Here, we comprehensively evaluated the preclinical efficacy of BI-2493, a first-in-class allele-agnostic mutant-KRAS inhibitor (panKRASi), in pancreatic ductal adenocarcinoma (PDAC).
View Article and Find Full Text PDFDiscovery of an allosteric 14-3-3 inhibitor for suppressing NRF2-driven cancer phenotypic screening and chemoproteomic-based target deconvolution.
Chem Sci
August 2025
Jiang Su Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University Nanjing 210009 China
The NRF2 transcription factor is constitutively active in various cancers, functioning as an oncogenic driver for tumor progression and chemo/radiotherapy resistance. Despite the well-documented role of NRF2 overactivation in cancer, no targeted therapy is currently available. In this study, using a combination of phenotypic screening, chemoproteomics, and biochemical and cellular assays, we identified WS3 as a potent allosteric inhibitor of 14-3-3 that selectively inhibits NRF2 activity in tumor cells.
View Article and Find Full Text PDF